Oleunor N7e

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, the active ingredients in Oleunor N7e, are an amino acid mixture presented as a powder for oral use. It supports protein synthesis and metabolic balance in patients requiring nutritional supplementation, such as those with malnutrition, post‑operative recovery, or chronic disease.

GNH USA supplies Oleunor N7e as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Oleunor N7e is used as a nutritional amino acid supplement to address protein‑energy deficits and support metabolic recovery. - Protein‑energy malnutrition: helps restore nitrogen balance and promote lean body mass gain. - Post‑surgical recovery: provides essential amino acids to accelerate wound healing and muscle repair. - Chronic kidney disease (stage 3‑5) under dietary management: supplies tailored amino acids while limiting nitrogen load. - Inborn errors of metabolism (e.g., phenylketonuria) as part of specialized dietary therapy: offers controlled amino acid provision.

Amino acid mixtures can be associated with gastrointestinal and metabolic reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: transient discomfort after ingestion. - Diarrhea: loose stools occurring within hours. - Abdominal discomfort: cramping or bloating. - Flatulence: increased intestinal gas. - Headache: mild, self‑limiting. - Metallic taste: temporary alteration of taste perception.

Serious or Rare Side Effects: - Hyperammonemia: elevated blood ammonia levels requiring monitoring. - Allergic rash: skin eruption indicating hypersensitivity. - Anaphylaxis: rare, severe allergic reaction needing immediate care. - Electrolyte imbalance: disturbances in sodium, potassium, or calcium. - Metabolic acidosis: low blood pH in susceptible individuals. - Hepatic dysfunction: abnormal liver enzyme elevations.

When prescribing Oleunor N7e, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: adjust dose in patients with severe renal impairment. - Monitor liver enzymes: observe for signs of hepatic stress during prolonged therapy. - Evaluate for phenylalanine sensitivity: avoid in individuals with phenylketonuria. - Review concomitant medications: consider potential competition with levodopa or MAO inhibitors. - Pregnancy and lactation: use only if benefit outweighs risk; limited data available. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Oleunor N7e may interact with certain drugs that share transport pathways or metabolic processes.

Major Interactions (Avoid): - Levodopa therapy: large neutral amino acids can reduce levodopa absorption. - MAO inhibitors: risk of hypertensive crisis when combined with high‑dose amino acids. - Anticonvulsants (e.g., valproate): may alter amino acid metabolism.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: amino acid load can affect glucose control. - Thyroid hormone replacement: amino acids may interfere with absorption. - Antibiotics (e.g., tetracycline): chelation may reduce antibiotic efficacy.